Recurrent Genomic Alterations in Pediatric and Adult Central Nervous System Tumors Detected by Chromosomal Microarray: Difference between revisions
No edit summary |
No edit summary |
||
| Line 365: | Line 365: | ||
|Activation of MYC pathway is often seen with loss of 9p (CDKN2A/B), and 14q (MAX gene) and is reported to have a worse prognosis | |Activation of MYC pathway is often seen with loss of 9p (CDKN2A/B), and 14q (MAX gene) and is reported to have a worse prognosis | ||
|PMID:27090007; PMID:26061753; PMID:25263767 PMID:26061754; PMID:24335697; PMID:25664944;PMID:26061753; PMID:26941959; PMID:26824661 PMID:26061751 | |PMID:27090007; PMID:26061753; PMID:25263767 PMID:26061754; PMID:24335697; PMID:25664944;PMID:26061753; PMID:26941959; PMID:26824661 PMID:26061751 | ||
|- | |||
|Glioblastoma , grade IV, IDH mutant | |||
|'''Gain:''' 1/1q, 6p<br> | |||
'''Loss:''' 3p, 10, 13, 14, 15, 22 (3, 4q, 19q, 16p, 21q, 5p seen in age <40)<br> | |||
'''Amplification:''' CDK6, cyclin E2, CDK4, MET<br> | |||
'''Chromothripsis''' | |||
|'''Gain or Amplification:''' CDK4, CDK6, cyclin E2<br> | |||
'''Loss:''' PTEN | |||
|About 10% of glioblastomas; correspond closely to secondary glioblastoma with history of prior glioma. These cases often involve loss of 10q , gain of CDK4, CDK6, cyclin E2, and increase in copy number alterations. | |||
|PMID:26061754; PMID:25754088; PMID:28535583 PMID:25931051; PMID:26091668; PMID:25461780; PMID:27157931; PMID:25727226; PMID:26323991 PMID:26061751; PMID:29687258 | |||
|- | |||
| | |||
|Glioblastoma , grade IV, IDH wildtype | |||
|'''Loss:''' 4, 9p, 10, 13, 14, 15, 22 , (3, 4q, 19q, 16p, 21q, 5p loss in age <40)<br> | |||
'''Gain:''' 7, 19, 20 (1q, 12p, 11q, 9q, 4, 10p gain in age <40) <br> | |||
'''Amplification:''' EGFR, MDM4, CDK4, MET | |||
|'''Loss:''' homozygous CDKN2A/B, PTEN, RB1<br> | |||
'''Mutation:''' TERT, EGFR, PTEN, NF1, RB1, PIK3CA or PIK3R1, TP53<br> | |||
'''Amplification:''' EGFR, MDM4, MDM2, CDK4, PDGFRA, MET | |||
|Overall poor prognosis. Gain of 19q, amplification of EGFR, and homozygous loss of CDKN2A are seen primarily in patients over age 40. Co-gain of 19 and 20 may be associated with longer survival. | |||
|PMID:26061754; PMID:25754088; PMID:28535583 PMID:25931051; PMID:26091668; PMID:25461780; PMID:27157931; PMID:25727226; PMID:26061751 | |||
|- | |||
|'''MENINGIOMA''' | |||
|- | |||
| | |||
|Grade 1 | |||
| | | | ||